US Patent granted for Amal Therapeutics’ novel cancer vaccine technology platform
02.12.2015
The Geneva based startup Amal Therapeutics announced that a US patent had been granted for its novel cancer vaccine technology platform.
 Madiha Derouazi, Amal Therapeutics CEO.
|
 |
Amal Therapeutics SA ("Amal”), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled “MULTI-EPITOPIC VACCINE” by the US Patent and Trademark Office (USPTO). This patent covers Amal’s multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment of cancers.
This proprietary technology is applicable for the development of indication-tailored vaccines incorporating the University of Geneva exclusively licensed vector family. The versatile and flexible recombinant protein-based technology platform gives Amal’s vaccines the unique property to simultaneously activate killer and helper T cells; two subsets essential for potent anti-cancer immunity.
"The issuance of this patent is a significant step in Amal Therapeutics development plans and the recognition of the potential of Amal’s novel technology platform. This broadens our intellectual property position and establishes a solid foundation for future Amal’s R&D portfolio” said Madiha Derouazi, Amal Therapeutics CEO.
About Amal Therapeutics
Amal reaches milestone after milestone. The startup jumped this year from rank Nr. 98 in 2014 to Nr. 34 in the TOP100 Swiss Startups. Over the past year, major investors have piled into Amal and an experienced pharmaceutical manager took over as president of the supervisory board. This year, Amal also made headlines on the technological/medical side of things. Cancer Research published Amal's study results in June. Cancer Research is no run-of-the-mill journal, but the most-cited one. In October 2015, Amal announced the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties.
A startup supported by Venture Kick and venturelab
Amal Therapeutics was supported by Venture Kick from the start and won the final of the program in 2012. CEO Madiha Derouazi was also part of the Swiss national startup team in 2012, in Boston.